VERAXA Biotech And Voyager Acquisition Complete Business Combination; On June 11, 2026, VERAXA Will Commence Trading Its Shares Under The Symbol "VRXA"

VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp and will begin trading on NASDAQ under ticker VRXA on June 11, 2026. The company secured $27.5 million in senior secured note financing and up to $50 million in share purchase agreements to advance its pipeline of BiTAC-TCE and BiTAC-ADC cancer therapies. VERAXA presented promising preclinical data at AACR 2026 demonstrating superior safety profiles and matching efficacy compared to traditional TCEs.

VERAXA Biotech shares are trading higher after the company announced the appointment of Raju Willener as its CFO.

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and biopharmaceutical finance. The appointment comes as VERAXA advances its BiTAC® platform and oncology pipeline toward clinical development.

VERAXA Biotech Announces Appointment Of Raju Willener As CFO, Effective Immediately

VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency